Advancing age and loss of bone mass and strength are closely linked. Elevated osteoblast and osteocyte apoptosis and decreased osteoblast number characterize the age-related skeletal changes in humans and rodents. Similar to other tissues, oxidative stress increases in bone with age. This article reviews current knowledge on the effects of the aging process on bone and its cellular constituents, with particular emphasis on the role of reactive oxygen species (ROS). FoxOs, sirtuins and the p53 / p66 shc signaling cascade alter osteoblast number and bone formation via ROS-dependent and -independent mechanisms. Specifically, activation of the p53 / p66 shc signaling increases osteoblast / osteocyte apoptosis in the aged skeleton and decreases bone mass. FoxO activation in osteoblasts prevents oxidative stress to preserve skeletal homeostasis. However, while defending against stress FoxOs bind to -catenin and attenuate Wnt / T-cell cell factor transcriptional activity and osteoblast generation. Thus, pathways that impact longevity and several diseases of ageing might also contribute to age-related osteoporosis.
Introduction
With advancing age, the amount of bone resorbed by the osteoclasts is not fully restored with bone deposited by the osteoblasts and this imbalance leads to bone loss. Thus, aging and osteoporosis are intimately linked. The decline in whole bone strength is due to reductions in trabecular and cortical bone density, decreased cortical thickness and a marked increase in cortical porosity. 1, 2 Loss of cancellous bone mass in humans starts in the third decade while cortical bone begins to decline after the age of 50. 3 In women, the loss of bone occurs at a faster rate after the menopause, attesting to the adverse role of estrogen deficiency on bone mass and its contribution to the acceleration of skeletal involution with age. The critical pathogenetic mechanism leading to age-related skeletal fragility is impaired bone formation due primarily to insufficient number of osteoblasts. 4, 5 The defective osteoblast number in the aging skeleton has been attributed to a decrease in the number of mesenchymal stem cells, defective proliferation / differentiation of progenitor cells or diversion of these progenitors toward the adipocyte lineage, as well as to increased apoptosis. 6 However, it remains unclear which of these processes has a causal role in mediating the decreased bone formation with age.
Loss of bone mass and strength in rodents with advancing age, similar to humans, is associated with an increase in the prevalence of apoptotic osteoblasts and osteocytes and a corresponding decrease in osteoblast number and bone formation Aging mechanism M Almeida anion to H 2 O 2 and catalase converts H 2 O 2 to water and oxygen. Alternatively, ROS can be detoxified via reactions with thiolcontaining oligopeptides, the most abundant of which are glutathione and thioredoxin. Augmented mitochondrial damage with age, however, may result in excessive ROS production that damages proteins, lipids and DNA, leading to cell death. 18, 19 Oxidative stress results from an imbalance between excessive ROS or other oxidants and the capacity of the cell to build up an effective antioxidant response ( Figure 1 ). Genetic studies using murine models have elucidated that oxidative stress is responsible for age-related tissue damage and various disease states such as diabetes, cardiovascular diseases, cancer and neurodegeneration. In mice, the loss of bone caused by gonadectomy is prevented by antioxidants. 7, 20, 21 In addition, overexpression of the antioxidant thioredoxin-1 attenuates oxidative stress, as shown by 8-hydroxydeoxyguanosine (one of the major products of DNA oxidation) staining in bone tissue including osteoblasts, and prevents the decline in bone formation following streptozotocin-induced diabetes in mice. 22 Further support for a deleterious role of oxidative stress in bone is provided by the evidence that both osteoblast numbers and bone formation are decreased in mice treated with the pro-oxidant buthionine sulfoximine, 21 and that murine models of premature aging associated with oxidative damage exhibit osteoporosis. 23, 24 Importantly, mice with global deletion of the antioxidant gene Sod1 exhibit low bone mass, which worsens with age. 25 The skeletal features of the Sod − / − mouse are similar to the aged skeleton of a normal mouse and include decreased trabecular and cortical bone mass, lower osteoblast and osteoclast numbers associated with decreased expression of RANKL in bone ( Figure 1 ). Moreover, Sod1-deficient osteoblasts have higher ROS levels associated with increased apoptosis. Administration of the antioxidant vitamin C normalized bone mass, ROS levels and osteoblast lifespan in Sod − / − mouse. At the cellular level, oxidative stress decreases osteoblast and osteocyte lifespan, as highlighted by the evidence that administration of antioxidants abrogates osteoblast and osteocyte apoptosis in the bone of ovariectomized or aged mice. 17 In addition to its role in apoptosis, oxidative stress may inhibit osteoblast formation. 26 Indeed, the Wnt signaling pathway -critical for osteoblastogenesis -is attenuated by oxidative stress in vitro . Inhibition of Wnt / -catenin signaling by ROS is mediated by the FoxO transcription factors, as described in detail below. Other mechanisms that contribute to the inhibition of Wnt signaling by ROS include dephosphorylation and activation of GSK-3 , which is required for -catenin degradation, and increased expression of the Wnt signaling inhibitor Dkk1. 27 -30 Osteocytes -former osteoblasts buried in the bone matrixare long-lived cells and are thus more prone to suffer the ravaging effects of aging. Osteocytes orchestrate bone resorption and formation via production of RANKL and sclerostin, respectively, in response to hormonal and mechanical stimuli. 31 The elevated osteocyte apoptosis with age is associated with diminished levels of RANKL and sclerostin protein in bone. 7, 13 Thus, oxidative stress or other age-intrinsic mechanisms may alter bone remodeling via decreasing the number and, most probably, the synthetic capacity of osteocytes. Why these mechanisms have a different overall effect on the rate of remodeling in cancellous versus cortical bone, remains unclear.
However, ROS are not always harmful. ROS produced in a regulated manner during cellular metabolism have beneficial roles as mediators in signaling and defense processes including vasorelaxation, angiogenesis, production of erythropoietin and destruction of bacteria by macrophages. 32, 33 In addition, recent work has elucidated that ROS generation by the mitochondria is a causal factor in adipocyte differentiation. 34 Importantly, formation and activation of osteoclasts requires ROS. 35 In line with this, several different antioxidants prevent Aging mechanism M Almeida the increased bone resorption that follows loss of sex steroids. 20 RANKL stimulates ROS production that, in turn, is required for osteoclastogenesis. The plasma membrane-associated nicotinamide adenine dinucleotide phosphate oxidase oxidases Nox1 and Nox2 are an important source for the ROS required in osteoclastogenesis. Specifically, RANKL increases ROS through a TRAF6 / Rac1 / Nox1-dependent pathway in osteoclasts. 36, 37 Mitochondrial biogenesis and ROS production are also essential for the bone resorbing function of osteoclasts and the bone loss caused by estrogen deficiency. 38 Moreover, the mitochondria-targeted antioxidant MitoQ suppresses osteoclastogenesis. 39 This evidence illustrates the requirement for ROS produced by different cellular compartments in osteoclastogenesis. Taken together, these findings support the contention that ROS have an important role in skeletal homeostasis and that oxidative stress contributes to the adverse effects of aging on bone mass and strength, via actions in osteoclasts and osteoblasts.
Pathways in Skeletal Aging
The molecular mechanisms that connect aging to age-related diseases are not well understood. A large effort of aging research has focused on genes and signaling pathways that control the rate of aging, the majority of which was initially identified in lower organisms. In particular, FOXO, sirtuins and p66 shc proteins can alter diseases of aging in mammals and might have a role in age-related skeletal involution.
FoxO transcription factors. Initial interest in FoxO transcription
factors stemmed from their role in longevity in Caenorhabditis elegans and Drosophila . 40, 41 Genetic work in mice has also shown that FoxOs can reduce the impact of age-related tissue damage and several pathologies including neurodegeneration, metabolic diseases and cancer. 42 These actions underscore the critical role of FoxOs in defense against oxidative stress. 43 Mammalian FoxO1, 3 and 4 activity is inhibited by growth factors and the insulin signaling pathways and stimulated by nutrient depletion and a plethora of ROS-induced post-translational modifications. 44 Recent studies have uncovered a fundamental role for FoxOs in skeletal homeostasis. Combined somatic deletion of FoxO1, 3 and 4 in adulthood resulted in increased oxidative stress in bone and bone loss at both cancellous and cortical sites 45 ( Figure 1 ). The decreased bone mass was due to deficient bone formation and resulted from decreased osteoblast number and increased osteoblast apoptosis. In contrast, mice with a gain of function of FoxO3 in osteoblasts exhibited decreased oxidative stress and osteoblast apoptosis, as well as increased osteoblast number, bone formation rate and bone mass. In line with the contention that FoxOs exert a critical role in defense against oxidative stress in osteoblasts, deletion of FoxO1 in col1a1-expressing cells decreased osteoblast numbers and bone mass as a consequence of increased oxidative stress. 46 FoxO1 deletion also attenuated protein synthesis in osteoblasts, leading to diminished levels of glutathione and col-lagen1. FoxO1 stimulates protein synthesis by partnering with ATF4 -a transcription factor that is an integral component of the pathway controlling amino acid import that protects against stress. 46 Beside ATF4, FoxOs interact with other transcription factors and coactivators that are critical for osteoblast formation. Indeed, FoxO1 binds to Runx2 in osteoblasts, as well as in prostate cancer cells. 47 This association is independent of the DNA-binding activity of FoxO1 and can repress or stimulate Runx2 activity.
As mentioned earlier, one of the main inhibitors of FoxO transcriptional activity is insulin. It has recently been shown that insulin signaling in osteoblasts is a positive regulator of postnatal bone acquisition. 48, 49 Mice lacking the insulin receptor in osteoblasts had reduced trabecular bone volume secondary to decreased bone formation and lower osteoblast numbers. These mice had also reduced osteoclast numbers in bone. Thus, insulin acting via the insulin receptor, similar to the actions FoxOs, in osteoblasts has a positive effect on bone formation. This work strongly suggests that targets other than inhibition of FoxOs are responsible for the increased bone mass promoted by insulin signaling. In contrast, insulin signaling in osteoblasts favors bone resorption by preventing the stimulatory action of FoxO1 on Opg. 49 These lines of evidence clearly show that FoxOs have critical functions in skeletal homeostasis.
FoxO-Wnt signaling cross-talk. -Catenin has an indispensable role in promoting T-cell cell factor (TCF) / lymphoid enhancer-binding factor transcription. In addition, -catenin is an essential co-activator of FoxOs. 16, 50 Oxidative stress induces the association of FoxOs with -catenin, and -catenin is required for the stimulation of FoxO target genes in osteoblasts and other cell types. Moreover, the interaction between the -catenin ortholog, BAR-1 and the FoxO ortholog DAF-16 is required for oxidative stress-induced expression of the DAF-16 target gene sod-3, resistance to oxidative damage and lifespan extension in C. elegans . 50 Oxidative stress induced by H 2 O 2 promotes FoxO-mediated transcription at the expense of Wnt / TCF-mediated transcription and osteoblast differentiation. 16 Similar to oxidative stress, nutrient deprivation promotes the association of -catenin with FoxOs, rather than with TCF, to modulate the gluconeogenic response in the liver. 51 In view of the role of -catenin on cell proliferation / differentiation and osteoblast generation, not only during development but also postnatally, 52, 53 and the role of FoxOs in defense against stress, the ability of FoxOs to sequester -catenin might restrict the proliferation / differentiation of osteoblast progenitors and contribute to the decreased bone formation and loss of bone mass during aging. 54 In osteoblasts and osteocytes, -catenin signaling increases Opg and decreases RANKL expression to attenuate osteoclastogenesis. 55 -57 In line with the inhibitory effect of oxidative stress on -catenin / TCF-mediated transcription, the expression of Opg and other Wnt-target genes decrease with age in murine bone. 16, 17 It is unknown whether the decrease in Opg contributes to the increase in cortical bone remodeling seen with age.
Lipid oxidation has a critical role in the development of atherogenesis and, epidemiological evidence shows that atherosclerosis and osteoporosis are linked. Importantly, ROS / FoxO suppression of Wnt signaling may be also the mechanism by which lipid oxidation contributes to the decline in osteoblast number and bone formation that occurs with aging. In the process of lipid oxidation, lipoxygenases, like Alox15, oxidize polyunsaturated fatty acids to form products that bind to and activate PPAR and generate pro-oxidants like 4-hydroxynonenal. 58 Lipid oxidation increases with age in bone and 4-hydroxynonenal, like H 2 O 2 , activates FoxOs that in turn Aging mechanism M Almeida attenuate -catenin / TCF-mediated transcription. 59 In addition, TCF-mediated transcription suppresses peroxisome proliferator-activated receptor (PPAR) expression, 60, 61 so that inhibition of -catenin / TCF transcriptional activity leads to an increase in PPAR levels. Oxidized polyunsaturated fatty acids promote PPAR association with -catenin and induce -catenin degradation, 59,62 thereby further decreasing -catenin / TCFmediated transcription. Via these mechanisms, lipid oxidation potentiates oxidative stress and may contribute to the decay in bone formation that occurs with aging. Oxidized lipids also stimulate apoptosis of osteoblastic cells and inhibit bone morphogenetic protein-2-induced osteoblast differentiation via ROS-independent mechanisms. 63 -65 Sirtuins. Sirtuins are NAD + -dependent deacetylases that slow aging in lower organisms and impact numerous diseases of aging in rodent models. 66 Sirtuins mediate a wide range of biological functions, spanning from DNA repair to energy metabolism and oxidative stress responses. These effects have been linked to the deacetylation of many important transcription factors including FoxOs and p53 by Sirt1. 67 In several tissues, Sirt1 exerts antioxidant effects by stimulating FoxO transcriptional activity. Moreover, Sirt3 -one of the Sirt family member present in the mitochondria -has been recently shown to control the levels of ROS themselves by multiple mechanisms. 68 Manipulation of Sirt1 activity, either pharmacologically with resveratrol or genetically, affects bone cells and alters bone mass. In vitro studies have revealed that resveratrol stimulates osteoblastogenesis and attenuates adipogenesis and osteoclastogenesis. The attenuation of adipogenesis and stimulation of osteoblastogenesis in bone marrow mesenchymal cells by resveratrol has been attributed to the inhibitory actions of Sirt1 on PPAR . 69 Resveratrol also upregulates Runx2 gene expression via the Sirt1 / FoxO3 axis to promotes osteogenesis of human mesenchymal stem cells. 70 In osteoclast progenitors resveratrol attenuates RANKL-induced NF-k activation and osteoclast formation. 71 In line with these findings is evidence that Sirt1 inhibits NF-k signaling by deacetylating RelA / p65. 72 Notably, long-term resveratrol administration to mice markedly reduced the signs of aging including loss of bone mass. 73 Resveratrol also prevented ovariectomy-induced osteoblast apoptosis and bone loss. 74 Physical activity stimulates bone formation and a decrease in mobility with age contributes to the loss of bone mass in humans. Hindlimb unloading in rodents is a commonly used model to mimic wasting disorders of unloading including osteoporosis. Administration of resveratrol to hindlimb suspended rats abrogated the loss of bone mass and strength in this model by preventing bone resorption and stimulating bone formation. 75 In line with the effects of resveratrol on bone, heterozygous Sirt1 deletion decreased bone formation and trabecular bone mass in male mice. 76 Moreover, targeted deletion of Sirt1 in osteoblasts decreases the bone formation rate and bone volume, whereas targeted deletion in osteoclast precursor cells leads to low bone mass due to increased osteoclast number. 77 Thus, Sirt1 controls bone mass by independently regulating osteoblast and osteoclast lineage cells. Whether the actions of Sirt1 in bone cells and bone mass depend on ROS attenuation or modulation of FoxO activity is unknown.
p53 -p66 shc signaling pathway. The tumor suppressor protein, p53, is a critical cellular stress sensor that is activated in response to ROS, DNA damage and other adverse stimuli such as oncogene activation and hypoxia. Thus, it is not surprising that p53 phosphorylation increases in the bone of male and female mice with aging or sex steroid deficiency. 7, 17 Depending on the degree of activation, p53 promotes growth arrest and repair, apoptosis or cellular senescence. 78 Genetically engineered mouse models of hyperactive mutant p53 have elucidated a role for activated p53 in organismal ageing. Such mice display early ageing phenotypes, including osteoporosis. 23, 79 In contrast, p53 null mice display a high bone mass phenotype, due to increased osteoblast number and bone formation rate. 80 The negative effect of p53 on osteoblast generation has been attributed to the repression of Runx2 and Osterix expression. 80, 81 In addition, p53 activity in osteoblasts attenuates osteoclast generation by decreasing M-CSF expression. 80 Importantly, p53 activation downstream of ROS was associated with decreased osteoblast proliferation in a murine model of FoxO1 deficiency in osteoblasts, 46 suggesting that the activation of p53 in aged bone might contribute to the decrease in osteoblast numbers and bone mass.
P53 is not only activated by ROS but can also modulate ROS levels. Indeed, in response to mild levels of stress, p53 can stimulate an antioxidant response program to prevent oxidative damage. However, when the stress source persists and the cellular repair process fails, prolonged p53 activation promotes cellular senescence or apoptosis by elevating ROS levels and this response is believed to be intrinsically linked to aging. 82 Indeed, the telomere theory of ageing postulates that progressive loss of telomere function triggers chronic activation of p53, implicating telomeres in the pathogenesis of age-related disorders. 43 Telomeres are DNA / nucleoprotein complexes at chromosome ends that function to preserve chromosomal integrity. Recent work has elucidated that p53, activated in response to telomere shortening, can lead to defects in mitochondrial biology and increased ROS, which are mediated by p53-induced PPAR coactivator 1 and PPAR coactivator 1 repression. 83 These findings provide a link between nuclear and mitochondrial dysfunction with age. It is currently unknown whether the pro-oxidant actions of p53 have any role in bone. Interestingly, defects in telomere maintenance, similar to p53 activation, impair osteoblast differentiation and promote osteoporosis in mice, 6 suggesting that a telomere dysfunction / p53 / ROS pathway might also be operative in osteoblast progenitor cells.
P53 stimulate ROS production via several mechanisms including an increase in p66 shc protein abundance. p66 Shc is an isoform of Shc that has an important role in mitochondrial ROS generation and translation of oxidative signals into apoptosis. 84 Specifically, oxygen-derived free radicals activate protein kinase C-isoform to induce Ser 36 phosphorylation of p66 Shc and translocation of the protein from the cytosol to mitochondria. In the mitochondria, p66 Shc functions as a redox enzyme to amplify the production of H 2 O 2 and promote apoptosis. 85 In line with these findings, either p53-null or p66 shc -null cells are relatively resistant to oxidant-induced apoptosis and exhibit lower endogenous ROS production and reduced oxidative damage to DNA as compared to wild-type cells. The phosphorylation of p53 and p66 Shc increases in bone with age, along with increased ROS and osteoblast apoptosis. 7 Conversely, apoptosis and p66 Shc phosphorylation in aged mice decrease with antioxidant administration. 17 Mice with global p66 Shc deficiency have lower ROS levels in bone and higher bone mass. 86 Aging mechanism M Almeida In addition, p66 shc -deficient osteoblasts exhibit increased resistance to oxidative stress. 87 Overall, these lines of evidence suggest that p53 and p66 shc might be causally involved in agerelated skeletal involution via ROS-dependent and -independent mechanisms.
Hormonal Control of Bone Mass via Modulation of ROS
An increase in the production of endogenous glucocorticoids with age, as well as enhanced sensitivity of bone cells to glucocorticoids represents another age-associated pathogenetic mechanism of involutional osteoporosis. 88 Glucocorticoids are strong inhibitors of bone formation by stimulating osteoblast apoptosis and decreasing osteoblast numbers. Mice with osteoblast / osteocyte-specific transgenic expression of 11 -HSD2, the enzyme that inactivates glucocorticoids, are partially protected from the adverse effects of aging on osteoblast and osteocyte apoptosis, bone formation rate and strength. Old 11 -HSD2 transgenic mice are also protected from the decreased bone vasculature volume and osteocyte lacunar-canalicular fluid observed in the aged wild-type controls. This, and the evidence that dehydration of bone decreases strength, suggests that endogenous glucocorticoids contribute to skeletal fragility in old age via cell autonomous effects on osteoblasts and osteocytes. In addition to their pro-apoptotic actions in mature cells, glucocorticoids attenuate osteoblast generation. Suppression of PI3K / Akt / GSK3 signaling and upregulation of the Wnt inhibitor DKK1 have been implicated in the attenuation of Wnt signaling and osteoblastogenesis by glucocorticoids. 89 -91 Recently, we and others have found that glucocorticoids stimulate ROS production and FoxO activity. 92 -94 Specifically, activation of a PKC / p66 shc / JNK signaling cascade is responsible for the pro-apoptotic effects of glucocorticoids on osteoblastic cells. In addition, activation of FoxOs, secondary to the attenuation of Akt by glucocorticoids is a cell-autonomous mechanism of Wnt / -catenin antagonism that contributes to the adverse effects of glucocorticoids on osteoblastogenesis. 94 This work suggests that at least some of the deleterious actions of glucocorticoids on bone might be mediated by ROS.
Similar to aging, gonadectomy promotes an increase in ROS and the phosphorylation of p53 and p66 shc in bone. 26 Estradiol, dihydrotestosterone or antioxidants completely reverse the effects of gonadectomy on these markers of oxidative stress. More strikingly, administration of antioxidants is as effective as sex steroid replacement in preventing the loss of BMD in gonadectomized female or male mice. P66 Shc is an essential mediator of the effects of oxidative stress, not only on apoptosis but also on NF-k activation and the expression of cytokines like tumor necrosis factor-and interleukin 6 in osteoblastic cells. 87 Sex steroids antagonize all these effects of oxidative stress by preventing PKC -induced p66 Shc phosphorylation via a mechanism that requires extracellular signal-regulated kinases. 7 Importantly, the DNA-binding function of estrogen receptor is not required for the antioxidant effects of estrogens on bone. 95 Consistent with the requirement of ROS for osteoclast generation and the in vivo evidence that sex steroids prevent bone loss via antioxidant effects, estradiol or dihydrotestosterone attenuate osteoclastogenesis and stimulate osteoclast apoptosis by a mechanism that involves activation of glutathione and thioredoxin reductases and inhibition of NF-k . 7, 20 Hence, an increase in endogenous glucocorticoids and the loss of sex steroids may contribute to age-related bone loss, at least in part, by increasing oxidative stress.
Summary and Conclusions
Advancing age is a major risk factor for the decline in bone mass and strength and, consequently, the rise in the incidence of bone fractures. Indeed, it is expected the incidence of osteoporotic-related fractures in the United States will reach 3 million annually by 2025. 96 Skeletal aging in the murine model closely recapitulates age-related skeletal changes in humans, including decreased osteoblast number as well as decreased bone mass and strength, and is associated with increased oxidative stress. Anabolic agents that promote osteoblast generation, such as intermittent parathyroid hormone or anti-sclerostin antibody administration, are efficacious in reversing age-related bone loss in rodents and in humans. 97 Interestingly, parathyroid hormone attenuates oxidative stress in the aged murine skeleton, suggesting that the antioxidant properties of parathyroid hormone might contribute to its efficacy in treating age-related osteoporosis. 17 In line with their pro-oxidant and deleterious role in other tissues, activation of p53 and p66 shc in bone with age or following sex steroid depletion increases osteoblast and osteocyte apoptosis and decreases bone mass. On the other hand, ROS stimulate the FoxO family of transcription factors and sirtuins to combat oxidative stress and maintain skeletal homeostasis. These studies suggest that evolutionary conserved pathways that mediate the age-related degeneration of several tissues, as well as organismal longevity, also have a role in the aging skeleton. Elucidation of the molecular mechanisms affected by aging in bone cells should reveal novel drug targets for the prevention / treatment of age-related skeletal involution.
